|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Recently, polymorphism in polyglutamine-coding region of Amplified In Breast cancer gene 1 (AIB1) was analyzed as an independent genetic risk factor influencing breast cancer onset in carriers of mutation in breast cancer predisposing gene 1 (BRCA1).
|
17234271 |
2007 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Here we assessed the influence of the two NCOA3 variants on breast cancer risk by genotyping an Australian case-control study population.
|
21601620 |
2011 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The AIB1 gene polyglutamine repeat length polymorphism and the risk of breast cancer development.
|
20422428 |
2011 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Studies were included in the meta-analysis if they met all the predetermined criteria, such as: (a) case-control or cohort studies; (b) the primary outcome was clearly defined as BC; (c) the exposure of interest measured was AIB1 polyglutamine repeat length genotype; (d) provided relative risk (RR) or odds ratio (OR) estimates and their 95% confidence intervals (CIs).
|
23483928 |
2013 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results strongly suggest that contrary to previous studies, there is no significant effect of AIB1 genetic variation on BC risk in BRCA1 mutation carriers and provide an indication that there is also no strong risk modification in BRCA2 carriers.
|
15900600 |
2005 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
There was no evidence that risk of breast cancer depends on AIB1 CAG/CAA polymorphism status, even if affected women carry a mutation in BRCA1 or BRCA2.
|
15987430 |
2005 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Women with a 28 repeat allele for AIB1 had a significantly reduced risk of breast cancer (HR = 0.72, 95% CI, 0.51-1.00).
|
16244359 |
2006 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that AIB1 repeat genotype does not influence postmenopausal breast cancer risk among Caucasian women in the general population.
|
11056690 |
2000 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The AIB1 polyglutamine length did not affect BC risk among BRCA2 mutation carriers.
|
14648706 |
2004 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Because AR coactivators enhance transactivation of AR, in this report we evaluated the relationship of a CAG/CAA repeat length polymorphism in the AIB1/SRC-3 gene (amplified in breast cancer gene 1, a steroid receptor coactivator and an AR coactivator) with prostate cancer risk in a population-based case-control study in China.
|
11927493 |
2002 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Given the large sample size, with more than adequate power to detect previously reported effects, we conclude that the AIB1 glutamine repeat does not substantially modify risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
|
16434590 |
2006 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We found that these women were at significantly higher breast cancer risk if they carried alleles with at least 28 or 29 polyglutamine repeats at AIB1, compared with women who carried alleles with fewer polyglutamine repeats [odds ratio (OR), 1.59; 95% confidence interval (CI), 1.03-2.47 and OR, 2.85; 95% CI, 1.64-4.96, respectively].
|
11454686 |
2001 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Overall, we found no evidence of association for individuals who carried at least one AIB1 allele of 28 or 29 or more repeat with breast cancer risk.
|
22307791 |
2012 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Because of the impact of NCOA3 in antiestrogen therapy resistance, these polymorphisms might also influence therapy outcome in breast cancer.
|
15788663 |
2005 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Similarly, genes involved in hormone metabolism, including the AIB1 and AR genes, have been linked with altered breast cancer risk.
|
11921193 |
2002 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
AIB1, a member of the steroid receptor coactivator 1 family, has been cloned on 20q12 and is a candidate oncogene in human breast cancer.
|
16084947 |
2005 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, our results reveal an essential role of ACTR in control of breast cancer cell proliferation and implicate the ACTR-E2F1 pathway as a novel mechanism in antiestrogen resistance.
|
15169882 |
2004 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We have now investigated the role of the AIB1 protein in breast cancer cell lines.
|
11768608 |
2001 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We recently demonstrated that the E3 ubiquitin ligase adaptor speckle-type poxvirus and zinc finger (POZ) domain protein (SPOP) interacts directly with SRC-3 and promotes its cullin 3-dependent ubiquitination and proteolysis in breast cancer, thus functioning as a potential tumor suppressor.
|
23559371 |
2013 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We conclude that AIB1 is a major coactivator for hER in MCF-7 human breast cancer cells.
|
11050174 |
2000 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These genes had a specific ontological distribution and some of them have been linked to breast cancer in previous studies: AIB1, the two keratin genes KRT5 and KRT15, RAF1, WIF1 and MSH6.
|
18561318 |
2008 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
AIB1 was analyzed with immunohistochemistry in tissue microarrays of the Danish subcohort (N = 1396) of the International Breast Cancer Study Group's trial BIG 1-98 (randomization between adjuvant tamoxifen versus letrozole versus the sequence of the two drugs).
|
28766132 |
2017 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The role of AIB1 and PAX2 in primary breast cancer: validation of AIB1 as a negative prognostic factor.
|
23230135 |
2013 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Since SRC-3 was found to be amplified in breast cancer in 1997, the role of SRC-3 in cancer has been broadly investigated.
|
21647249 |
2011 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The AIB1 oncogene promotes breast cancer metastasis by activation of PEA3-mediated matrix metalloproteinase 2 (MMP2) and MMP9 expression.
|
18644862 |
2008 |